He’s setting the world of Inflammation and Immunology research on fire!
- tim78593
- 2 hours ago
- 2 min read
Today we are honored to have Dr. Josep Bassaganya-Riera, President and CEO of NImmune Biopharma, to talk about how his company is leveraging computational modeling and bioinformatics to develop new therapeutics.
You’ll hear about:
How Dr. Bassaganya-Riera became interested in immunology focused on lipids by starting his career as a veterinarian
Why lipids have a powerful anti-inflammatory effect & how it was discovered in veterinary medicine in cattle
How having a dad who was a bootstrapping entrepreneur selling pulleys shaped Dr. Bassaganya-Riera’s path toward problem solving, discovering new mechanisms in biotech, and serving public health problems,
How Dr. Bassaganya-Riera’s previous company was acquired by Abbvie even though it was in its early stages of modeling immunity health, and what role the anthrax scare played in it.
The amazing process of drug development for NX-13, now known as ABBVIE 113
Why the TITAN-X platform was kept in house and not sold off to Abbvie
The tremendous paradigm shift going on in drug discovery and clinical trials, and why it’s also a double-edged sword
Why TITAN-X from its very origins was built to be agnostic in microbiology and transcend its disciplines, and how that makes it even more valuable
Leveraging big data sets for clinical trials and using it to predict future diseases in humans
How a supercomputer called ShadoFax, running simulation, trillions at a time, became the largest model of immune systems and biodefense in 2012-2013
Why there is skepticism in using AI specifically ChatGPT for computational modeling
Why biotech companies are actually hiring computational biologists for the expected next wave of pharma discoveriesÂ
Dr. Bassaganya-Riera's best advice to a founder just starting out in the biotech field and why the field is actually not founder-friendly
How to focus a team with limited funding capital available for studiesÂ
Enjoy the show!
About Dr. Josep Bassaganya-RieraÂ
Dr. Josep Bassaganya-Riera is known for founding Landos Biopharma, which was acquired by AbbVie in 2024. He is also the founder and CEO of NImmune Biopharma, a late-stage biotech whose main assets are omilancor—a Phase-3-ready, once-daily, oral, gut-restricted therapeutic for UC with potentially fast-to-market follow-on opportunities in CD and Psoriasis—and NIM-1324  first- and potentially best-in-class once-daily, oral, systemically distributed LANCL2 agonist therapeutic for the treatment of Systemic Lupus Erythematosus (SLE). He has published over 300 peer-reviewed articles, book chapters and books on the acceleration of biopharmaceutical development and computational immunology, and he has contributed 200 patents in immunology and autoimmune disease treatment. He has raised over $250 million in non-dilutive and equity financing rounds. Dr. Bassaganya-Riera holds a degree in Veterinary Medicine from Universitat Autònoma de Barcelona and a Ph.D. in Nutrition and Immunology from Iowa State University.
Disclaimer
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.